Supposedly so is Toujeo, longer acting/peakless, just like Fiasp is supposedly shorter/faster acting. Whether that leads to lower A1C's is the question. Does it? Did they compare it to Novorapid in a randomized study? I'd be interested in seeing that if it was done.
You won't have to wait too long. ONSET 3 and 4 are comparing Fiasp and Novorapid in a double blind randomised study. The results are due out later this year. I know a few of the involved HCPs (and one of the clinics involved is mine). According to the senior consultant, a number of people have identified they are on Fiasp, but the key point about the study is that it has taken normal T1s with Hba1C between 7.5% and 10% and used them. Most aren't as heavily engaged as most of us are. It will be very interesting to see the outcome.
Personally, Fiasp lowering Hba1C isn't the reason I was interested. It was the reduced time from bolus to eating (30-45 mins to 0 mins) and the avoidance of post prandial highs. As it happens, after 6 weeks on Fiasp, with a prior six weeks on Novorapid, both using the closed loop I use, the same algorithm, and if anything, a higher carb diet than when on Novorapid, I saw an Hba1C drop from 5.8% to 5.1% which shocked me and I didn't expect. Now I'm n=1 but the other studies that Novo have done also suggest reductions, and generally people are seeing
good results with it.
My only question would be one of population. If someone discovers that they can much more "eat what they want" with an insulin with a faster response, do they then go and do this and stuff it all up again?
